Stock Events

Stock Events

Akari Therapeutics 

0
12
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-15MNet Income

Analyst Ratings

22.76Average Price Target
The highest estimate is 22.76.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLA1.MU. It's not an investment recommendation.
Tesla
4
TSLA
Schwab US Dividend Equity
3
SCHD
Vanguard S&P 500
3
VOO
SNDL
3
SNDL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in developing treatments for cystic fibrosis and other serious diseases, overlapping with Akari's focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals specializes in developing medications for eye diseases, rare diseases, and immune disorders, competing in similar therapeutic areas as Akari.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurology, rare diseases, and autoimmune disorders, areas that overlap with Akari's therapeutic focus.
AMGEN
AMGN
Mkt Cap196.12B
Amgen develops treatments for serious illnesses in areas like oncology and cardiology, and its work in immune disorders competes with Akari.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences focuses on antiviral drugs, liver diseases, and inflammatory and respiratory diseases, competing in the broader area of serious and rare diseases.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie works on chronic autoimmune diseases and more, with its broad focus on serious diseases including areas that compete with Akari's treatments.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk specializes in diabetes and obesity but is expanding into rare blood disorders, which could compete with Akari's pipeline.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad portfolio including treatments for rare diseases and inflammation, making it a competitor in some of Akari's key areas.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for a wide range of diseases, including those in competition with Akari's focus areas.

About

Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Show more...
CEO
ISIN
US00972G4055

Listings

STU
DE
CLA1.STU
MU
DE
CLAB.MU
MU
DE
CLA1.MU
F
DE
CLA1.F

0 Comments

Share your thoughts

FAQ

What is Akari Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Akari Therapeutics stocks are traded under the ticker CLA1.MU.
What is Akari Therapeutics revenue for the last year?▼
Akari Therapeutics revenue for the last year amounts to 0 EUR.
What is Akari Therapeutics net income for the last year?▼
CLA1.MU net income for the last year is -15M EUR.
In which sector is Akari Therapeutics located?▼
Akari Therapeutics operates in the Other sector.
When did Akari Therapeutics complete a stock split?▼
The last stock split for Akari Therapeutics was on March 31, 2026 with a ratio of 1:40.